［1］WU W,XU H,MENG Z,et al.Axl is essential for in-vitro angiogenesis induced by vitreous from patients with proliferative diabetic retinopathy［J］.Front Med(Lausanne),2021,8:787150.
［2］EL-KHOUEIRY AB,HANNA DL,LLOVET J,et al.Cabozantinib:An evolving therapy for hepatocellular carcinoma［J］.Cancer Treat Rev,2021,98:102221.
［3］NIU ZS,NIU XJ,WANG WH.Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance［J］.Future Oncol,2019,15(6):653-662.
［4］AUYEZ A,SAYAN AE,KRIAJEVSKA M,et al.AXL receptor in cancer metastasis and drug resistance:When normal functions go askew［J］.Cancers(Basel),2021,13(19):4864.
［5］ENGELSEN AST,LOTSBERG ML,ABOU KHOUZAM R,et al.Dissecting the role of AXL in cancer immune escape and resistance to immune checkpoint inhibition［J］.Front Immunol,2022,13:869676.
［6］YAN S,VANDEWALLE N,DE BEULE N,et al.AXL receptor tyrosine kinase as a therapeutic target in hematological malignancies:Focus on multiple myeloma［J］.Cancers(Basel),2019,11(11):1727.
［7］GOYETTE MA,COTE JF.AXL receptor tyrosine kinase as a promising therapeutic target directing multiple aspects of cancer progression and metastasis［J］.Cancers(Basel),2022,14(3):466.
［8］FALCONE I,CONCIATORI F,BAZZICHETTO C,et al.AXL receptor in breast cancer:Molecular involvement and therapeutic limitations［J］.Int J Mol Sci,2020,21(22):8419.
［9］ZHANG G,KONG X,WANG M,et al.AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma［J］.Oncol Lett,2018,15(2):1900-1906.
［10］SONG W,WANG H,LU M,et al.AXL inactivation inhibits mesothelioma growth and migration via regulation of p53 expression［J］.Cancers(Basel),2020,12(10):2757.
［11］TANAKA M,SIEMANN DW.Axl signaling is an important mediator of tumor angiogenesis［J］.Oncotarget,2019,10(30):2887-2898.
［12］LECHERTIER T,REYNOLDS LE,KIM H,et al.Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth［J］.Nat Commun,2020,11(1):2810.
［13］CHAI ZT,ZHANG XP,AO JY,et al.AXL overexpression in tumor-derived endothelial cells promotes vessel metastasis in patients with hepatocellular carcinoma［J］.Front Oncol,2021,11:650963.
［14］XIAO Y,ZHAO H,TIAN L,et al.S100A10 is a critical mediator of GAS6/AXL-induced angiogenesis in renal cell carcinoma［J］.Cancer Res,2019,79(22):5758-5768.
［15］PICON H,GUDDATI AK.Mechanisms of resistance in head and neck cancer［J］.Am J Cancer Res,2020,10(9):2742-2751.
［16］LAMOUILLE S,XU J,DERYNCK R.Molecular mechanisms of epithelial-mesenchymal transition［J］.Nat Rev Mol Cell Biol,2014,15(3):178-196.
［17］REICHL P,DENGLER M,VAN ZIJL F,et al.Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma［J］.Hepatology,2015,61(3):930-941.
［18］HUA W,ZHAO Y,JIN X,et al.METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition［J］.Gynecol Oncol,2018,151(2):356-365.
［19］ANTONY J,TAN TZ,KELLY Z,et al.The GAS6-AXL signaling network is a mesenchymal(Mes) molecular subtype-specific therapeutic target for ovarian cancer［J］.Sci Signal,2016,9(448):ra97.
［20］HE L,LEI Y,HOU J,et al.Implications of the receptor tyrosine kinase Axl in gastric cancer progression［J］.Onco Targets Ther,2020,13:5901-5911.
［21］ZAMAN A,BIVONA TG.Targeting AXL in NSCLC［J］.Lung Cancer(Auckl),2021,12:67-79.
［22］NOVIKOV NM,ZOLOTARYOVA SY,GAUTREAU AM,et al.Mutational drivers of cancer cell migration and invasion［J］.Br J Cancer,2021,124(1):102-114.
［23］MELCHIONNA R,SPADA S,DI MODUGNO F,et al.The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation［J］.EMBO Rep,2020,21(11):e50078.
［24］TAI KY,SHIEH YS,LEE CS,et al.Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1［J］.Oncogene,2008,27(29):4044-4055.
［25］COLAVITO SA.AXL as a target in breast cancer therapy［J］.J Oncol,2020,2020:5291952.
［26］TANAKA M,DYKES SS,SIEMANN DW.Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling［J］.Clin Exp Metastasis,2021,38(3):321-335.
［27］SHEN Y,ZHANG W,LIU J,et al.Therapeutic activity of DCC-2036,a novel tyrosine kinase inhibitor,against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET［J］.Int J Cancer,2019,144(3):651-664.
［28］BOTTAI G,RASCHIONI C,SZEKELY B,et al.AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients［J］.NPJ Breast Cancer,2016,2:16033.
［29］D'ERRICO G,ALONSO-NOCELO M,VALLESPINOS M,et al.Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance［J］.Oncogene,2019,38(27):5469-5485.
［30］HAIDER C,HNAT J,WAGNER R,et al.Transforming growth factor-β and Axl induce CXCL5 and neutrophil recruitment in hepatocellular carcinoma［J］.Hepatology,2019,69(1):222-236.
［31］CHOI JY,LEE H,KWON EJ,et al.TGFβ promotes YAP-dependent AXL induction in mesenchymal-type lung cancer cells［J］.Mol Oncol,2021,15(2):679-696.
［32］GHISO E,MIGLIORE C,CICIRIELLO V,et al.YAP-dependent AXL overexpression mediates resistance to EGFR inhibitors in NSCLC［J］.Neoplasia,2017,19(12):1012-1021.
［33］LIN JZ,WANG ZJ,DE W,et al.Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer［J］.Oncotarget,2017,8(25):41064-41077.
［34］SUN ZG,LIU JH,ZHANG JM,et al.Research progress of Axl inhibitors［J］.Curr Top Med Chem,2019,19(15):1338-1349.
［35］SHEN Y,CHEN X,HE J,et al.Axl inhibitors as novel cancer therapeutic agents［J］.Life Sci,2018,198:99-111.
［36］LUDWIG KF,DU W,SORRELLE NB,et al.Small-molecule inhibition of Axl targets tumor immune suppression and enhances chemotherapy in pancreatic cancer［J］.Cancer Res,2018,78(1):246-255.
［37］ZHU C,WEI Y,WEI X.AXL receptor tyrosine kinase as a promising anti-cancer approach:Functions,molecular mechanisms and clinical applications［J］.Mol Cancer,2019,18(1):153.
［38］OKURA N,NISHIOKA N,YAMADA T,et al.ONO-7475,a novel AXL inhibitor,suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer［J］.Clin Cancer Res,2020,26(9):2244-2256.
［39］STEWART CA,GAY CM,RAMKUMAR K,et al.Lung cancer models reveal severe acute respiratory syndrome coronavirus 2-induced epithelial-to-mesenchymal transition contributes to coronavirus disease 2019 pathophysiology［J］.J Thorac Oncol,2021,16(11):1821-1839.
［40］SANG YB,KIM JH,KIM CG,et al.The development of AXL inhibitors in lung cancer:Recent progress and challenges［J］.Front Oncol,2022,12:811247.
［41］LECONET W,LARBOURET C,CHARDES T,et al.Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy［J］.Oncogene,2014,33(47):5405-5414.
［42］BOSHUIZEN J,KOOPMAN LA,KRIJGSMAN O,et al.Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors［J］.Nat Med,2018,24(2):203-212.